Table 1. HCC in Patient Treated with IFN-Free Regimens Including DAAs.
| REF. | Type of Study | Number of Patients | Patients with Previous Hcc, N (%) | Patients with Previous Liver Transplant, N (%) | Patients Treated with DAA (IFN-free) Regimens, N (%) | Patients Not Treated for Hcv, N (%) | Patients Who Developed Hcc After DAA Treatment, N (%) | Patients Who Developed Hcc Without DAA Treatment, N (%) | Statistical Difference in Risk of Hcc Between Patients Receiving or Not Receiving DAAs |
|---|---|---|---|---|---|---|---|---|---|
| ( 5 ) | Cohort study | 406a | 29 (7.1) | 0 (0) | 406 (100) | 0 (0) | 17 (4.1) | Not available | Not available |
| ( 6 ) | Cohort study | 58 | 58 (100) | 0 (0) | 58 (100) | 0 (0) | 16 (27.6) | Not available | Not available |
| ( 7 ) | Cohort study | 81 | 81 (100) | 81 (100) | 18 (22)b | 63 (78) | 5 (27.5) | 6.63 (9.5) | P = 0.06 |
| ( 8 ) c | Cohort study | 314 | 314 (100) | 314 (100) | 314 (100) | 0 (0) | 7 (2.2) | Not available | Not available |
| 267 | 267 (100) | 0 (0) | 189 (71) | 78 (29) | 0.73 /100 person-months | 0.66/100 person-months | P = 0.087 | ||
| 79 | 79 (100) | 0 (0) | 13 (16.5) | 66 (83.5) | 1.73/100 person-months | 1.11/100 person-months | P = 0.748 | ||
| ( 10 ) | Case series | 19 | 19 (100) | 0 (0) | 19 (100) | 0 (0) | Not availabled | Not available | Not available |
| ( 11 ) | Cohort study | 54 | 0 (0) | 0 (0) | 54 (100) | 0 (0) | 4 (7.4) | Not available | Not available |
| ( 12 ) | Cohort study | 926 | 926 (100)e | 0 (0) | 27 (2.9) | 861 (93.0)f | 8 (29.6) | 553 (64.2) | Not available |
| ( 13 ) | Cohort study | 344 | 59 (17.2) | 0 (0) | 344 (100) | 0 (0) | 26 (7.5) | Not available | Not available |
| ( 14 ) | Cohort study | 605 | Not available | Not available | 77 (12.7) | 0 (0) | 2 (2.6) | Not available | Not available |
aAll patients had decompensated cirrhosis.
bPatients received DAA treatment before liver transplant.
cReference (9) comprised data from three different cohorts.
dAuthors estimated a frequency of HCC recurrence of 6.6-5.2% after DAA treatment.
eAll patients had a recent history of HCC within 2 years from HCC treatment (radio-frequency ablation).
f38/926 (4.1%) were treated with IFN based treatments, 26/38 (68%) had HCC recurrence.